Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondria quality control in disease.
Market:
Capacity Bio's lead focus is neurodegeneration and muscular disorders, including Parkinson’s, ALS, and DMD which targets multibillion opportunities.Technology:
Capacity Bio has a unique set of drugs that improve mitochondrial quality control by targeting receptors on the cell surface.Advantages:
- Engage target quickly and efficiently
- No need to enter the cell or mitochondria
- Safe and effective
Development Stage:
- Pre-clinical
Patents Issued:
- Coming soon
Select Publications:
Contact:
Website: capacitybio.comEmail: info@capacitybio.com
Back to Top
Portfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.